Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Cash from Operations: 2022-2025

Historic Cash from Operations for Centessa Pharmaceuticals (CNTA) over the last 4 years, with Sep 2025 value amounting to -$58.3 million.

  • Centessa Pharmaceuticals' Cash from Operations fell 172.63% to -$58.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$180.8 million, marking a year-over-year decrease of 38.76%. This contributed to the annual value of -$142.1 million for FY2024, which is 11.40% up from last year.
  • As of Q3 2025, Centessa Pharmaceuticals' Cash from Operations stood at -$58.3 million, which was down 159.72% from -$22.5 million recorded in Q2 2025.
  • In the past 5 years, Centessa Pharmaceuticals' Cash from Operations registered a high of -$21.4 million during Q3 2024, and its lowest value of -$59.9 million during Q2 2022.
  • Its 3-year average for Cash from Operations is -$40.0 million, with a median of -$40.6 million in 2024.
  • Examining YoY changes over the last 5 years, Centessa Pharmaceuticals' Cash from Operations showed a top increase of 44.67% in 2025 and a maximum decrease of 172.63% in 2025.
  • Quarterly analysis of 4 years shows Centessa Pharmaceuticals' Cash from Operations stood at -$51.6 million in 2022, then skyrocketed by 39.78% to -$31.1 million in 2023, then slumped by 37.84% to -$42.8 million in 2024, then plummeted by 172.63% to -$58.3 million in 2025.
  • Its last three reported values are -$58.3 million in Q3 2025, -$22.5 million for Q2 2025, and -$57.2 million during Q1 2025.